Featured Education

nmdp-mds3_1729518959
soho-2024-enduring-banner-445x250-02-02-02_1727985795
p24011-lms-thumb_1726675197
P23033 LMS Thumb
p24034-obesity-aafp-lms-thumbnail-445x250px_1723738749
lms-thumbnail-445-x-250_1720799794

On Demand Activities

Therapeutics Areas
Learner Specialties
Expires After
Advances in Non-Hodgkin Lymphoma Care: Navigating New and Emerging Treatments
In this first episode, “Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” learn from expert faculty about unmet needs for patients with NHL based on an understanding of disease- and patient-related characteristics. Additionally, learn how to best assess eligible patients among new and emerging CAR T-cell and bispecific antibody therapies. Expert faculty will also discuss both the mechanisms of action of CAR T-cell and bispecific antibodies. This episode will conclude with a patient case study, which will consist of a dialogue between faculty.
Impact of Prevention: Updates in Vaccine Development
Healthcare providers (HCPs) encounter significant challenges in vaccine acceptance. A critical need exists among primary care providers (PCPs) to remain abreast of the continuously evolving vaccination landscape. As such, PCPs need to be able to evaluate the burden of vaccine-preventable diseases, provide well-founded recommendations for vaccine measures, and apply appropriate strategies to address vaccine hesitations.
The Burden of Vaccine-Preventable Disease: Assessing Risk in Older Adults
Healthcare providers (HCPs) encounter significant challenges in vaccine acceptance. A critical need exists among primary care providers (PCPs) to remain abreast of the continuously evolving vaccination landscape. As such, PCPs need to be able to evaluate the burden of vaccine-preventable diseases, provide well-founded recommendations for vaccine measures, and apply appropriate strategies to address vaccine hesitations.
DIABESITY DIALOGUES:Beyond Inertia: Advancing T2D Care With Innovative Basal Insulin Strategies
Discover the forefront of diabetes care at Diabetes Dialogues LIVE, targeting the latest in once-weekly basal insulin therapy, including unique mechanism of action and pharmacokinetic/pharmacodynamic properties. Join fellow endocrinologists to unpack recent safety and efficacy data. Additionally, hear discussion about basal insulin therapy for patient care and how to best ensure adherence through effective T2D management. Delve into clinical trials outcomes, glycemic control, weight management, and hypoglycemia risks. Engage in essential scientific discourse to shape the future of diabetes treatment. Do not miss this event for an insightful blend of data and practice. This activity is derived from the Live ISS Meeting at ENDO, originally held on June 1, 2024.
Keeping Up with CAR T-cell Therapy: A Case-based Challenge of CART in NHL + MM
Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and expert-led discussions, you’ll be empowered to manage complex treatment scenarios, deliver comprehensive patient education, and navigate even the trickiest treatment-related challenges.
Lessons Learned from Your Patient's Family After Their Loved One Has Died
Our time spent with patients and their families should not end with the transfer of the patient to hospice care. The patient may even resist such a transfer, feeling abandoned by their medical oncology team. Treatment for treatment’s sake is really bad medical care. Doing an effective job of preparing the patient and family for end of life needs to be the ultimate goal as treatments begin to no longer work. Due to having no contact with families after the patients have died results in losing teaching moments for the team that provided her breast cancer treatment. There is great value in incorporating the family’s needs and understanding into the treatment planning process from the beginning so they are better prepared at the end of her life and beyond.
Scroll to Top